On November 2nd, the Letter on Carrying out the Eighth Centralized Purchasing of Medical Consumables in Sanming Purchasing Alliance issued by official website mentioned that Hebei Medical Insurance Bureau will be entrusted to take the lead in organizing the eighth centralized purchasing of medical consumables, involving 2 kinds of medical consumables, including rigid breathable contact lenses (commonly known as "OK lenses") for corneal shaping, artificial bones, cardiac fixators and intracranial stents. All alliance cities need to submit the results to Sanming Purchasing Alliance before November 8th.
According to official website, at present, Sanming Alliance members have covered 3 prefecture-level cities in 16 provinces and 4 national medical reform demonstration counties, covering a regional population of over 16 million. The relevant person in charge of Sanming Medical Insurance Bureau said in an interview with Securities Daily that the centralized procurement was mainly to follow up the eighth centralized procurement of medical consumables led by Hebei Medical Insurance Bureau. Previously, Sanming Purchasing Alliance has carried out centralized purchasing of medical consumables for many times, and with the joining of Sanming Purchasing Alliance, the scope of centralized purchasing of 2 kinds of medical consumables in Hebei Province will be larger and wider.
The investment director of an investment institution told the Securities Daily reporter, "The 2 kinds of medical consumables included in the centralized purchase this time are basically consumables within the scope of medical insurance, mainly in the fields of orthopedics, cardiovascular interventional surgery, etc., with large clinical consumption and relatively high single value of consumables. The main reason for the inclusion of OK glasses in the collection is that the unit price of about 1, yuan is too high, and it needs to be repurchased with the development of eyeballs, which greatly increases the pressure on consumers' medical and health expenditures. "
Deng Zhidong, general manager of Hainan Boao Medical Technology Co., Ltd. told the Securities Daily reporter, "There are many selected products and rich categories in this collection. In addition, this is the eighth round of centralized purchasing of medical consumables in Sanming Purchasing Alliance, which shows that centralized purchasing of medical insurance will be further accelerated and expanded, and the national centralized purchasing of medicines will gradually enter the stage of normalization and institutionalization. This will help promote the' three medical linkages' and promote the formation of a new pattern of market development driven by fair competition, quality assurance and innovation. "
"The core of centralized purchasing is to exchange quantity for price. Recently, centralized purchasing of consumables mostly focuses on low-value consumables or consumables with high domestic production rate. After the full implementation of the procurement of medical consumables, a few successful bidders will * * * enjoy 6% to 7% of the national market, and finally form a pattern in which the head enterprises with strong innovation ability occupy a larger market share, and the consumables enterprises with poor innovation ability will be gradually eliminated, and the industry concentration will gradually increase. " Qin Liang, senior investment consultant of East Hi-Tech, said in an interview with a reporter from Securities Daily.
Qin Liang said, "Centralized purchasing of medical consumables is similar to the previous centralized purchasing of drugs, with the purpose of encouraging enterprises to enhance R&D and innovation and realize domestic autonomy in the field of high-end equipment and consumables. For medical device manufacturers, in the long run, it is a process of promoting' qualitative change', which requires them to continuously increase product research and development and seek more increments in innovation and medical value. For innovative high-value consumables enterprises, we should consider the advantages and disadvantages of competing products more in product research and development, and make innovative and differentiated products. "
"The existing centralized purchasing policy has changed from lowering the price in the past to a mature interest control mechanism to promote the development of industry norms, lower the price difference between middlemen, leave a certain profit margin for enterprises and innovate R&D expenses." The above investment director told reporters. "This move is especially beneficial to small and medium-sized innovative medical device companies. The biggest problem of these companies before was that they had good products and no good channels, so they could not form good performance. However, in the context of centralized procurement, channel and sales problems will be solved, and enterprises only need to make the products well, and then control the related expenses and product prices."
Deng Zhidong said, "Under the trend of normalization of centralized procurement, pharmaceutical enterprises need to optimize their development strategies, clarify their development goals and business models, identify their market positioning and target customers, provide higher-level and more diversified quality services, build an ecosystem of drug research and development, use advanced technology to empower them, improve quality, reduce costs and increase efficiency, effectively control risks, and realize enterprise transformation, upgrading and innovation."
if you want to know more financial news in real time, please follow us.